Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Surveillance (PMS) Study for Ngenla Prefilled Pen in Pediatric Patients Who Have Endogenous Growth Failure Due to an Inadequate Secretion of Endogenous Growth Hormone in Korea

NCT05509894 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05509894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05509894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Surveillance (PMS) Study for Ngenla Prefilled Pen in Pediatric Patients Who Have Endogenous Growth Failure Due to an Inadequate Secretion of Endogenous Growth Hormone in Korea
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
June 20, 2024
Completion date
September 23, 2026
Enrollment
565 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric growth hormone deficiency